Valuation: Biora Therapeutics, Inc.

Capitalization 818K 688K 628K 599K 1.11M 74.22M 1.15M 7.31M 2.89M 35.67M 3.07M 3.01M 128M P/E ratio 2022
-0.66x
P/E ratio 2023 -0.17x
Enterprise value 33.43M 28.09M 25.67M 24.46M 45.38M 3.03B 47.18M 299M 118M 1.46B 125M 123M 5.22B EV / Sales 2022
422x
EV / Sales 2023 17,337x
Free-Float
98.28%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0.34
3 years 0
Extreme 0
67
5 years 0
Extreme 0
1,550
10 years 0
Extreme 0
3,980
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 07/11/2021
Chief Executive Officer 58 31/08/2021
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 51 31/05/2014
Chairman 63 31/10/2021
Director/Board Member 59 07/11/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-99.00%0.00% - - 4
+0.86%-1.68%+11.01%+100.34% 50.29B
+0.89%+5.90%+69.68%+8.08% 42.11B
-0.21%-2.88%+87.04%+653.73% 31.96B
+3.49%+1.34%-6.18%-21.49% 26.75B
+5.70%+9.41%+85.60%-37.32% 19.95B
-1.35%-7.58%+39.46%-30.45% 19.08B
+5.77%+10.41%+144.57% - 12.63B
+4.42%+5.25%+64.52%+138.65% 11.89B
+0.11%+2.66%+31.27%+150.00% 11.82B
Average -7.92%-1.00%+58.55%+120.19% 22.65B
Weighted average by Cap. +1.70%-1.07%+50.90%+130.00%
See all sector performances

Financials

2022 2023
Net sales 305K 256K 234K 223K 414K 27.67M 430K 2.73M 1.08M 13.3M 1.14M 1.12M 47.59M 4K 3.36K 3.07K 2.93K 5.43K 363K 5.64K 35.74K 14.15K 174K 15K 14.69K 624K
Net income -38.16M -32.06M -29.3M -27.91M -51.79M -3.46B -53.84M -341M -135M -1.66B -143M -140M -5.95B -124M -104M -95.31M -90.8M -168M -11.26B -175M -1.11B -439M -5.41B -465M -456M -19.37B
Net Debt 99.26M 83.4M 76.23M 72.62M 135M 9B 140M 887M 351M 4.33B 372M 365M 15.49B 32.62M 27.4M 25.05M 23.86M 44.27M 2.96B 46.02M 291M 115M 1.42B 122M 120M 5.09B
More financial data * Estimated data
Logo Biora Therapeutics, Inc.
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
Employees
58
More about the company
Date Price Change Volume

Delayed Quote OTC Markets, February 03, 2026 at 07:38 pm

More quotes

Quarterly revenue - Rate of surprise